Grants and Benefits. Schedule 3.29 provides a list of all material pending and outstanding grants, incentives, Tax benefits, subsidies and other similar benefits or incentives, and all applications therefor (collectively, “Grants”), provided by a Governmental Authority to or for the benefit of the Company or any of its Subsidiaries or applicable to or affecting any of their respective businesses, properties, rights or assets. The Company provided to Buyer, prior to the date hereof, true and correct copies of all documents evidencing Grants submitted by the Company or any of its Subsidiaries, and all letters of approval and supplements thereto, granted to the Company or any of its Subsidiaries. Schedule 3.29 sets forth a summary of the Company’s estimated savings and benefits under the Grants for the time periods and types of savings and benefits specified therein. Except as set forth on Schedule 3.29, the Company or its Subsidiary, as appropriate, is in compliance, in all material respects, with the terms and conditions of their respective Grants and has duly fulfilled, in all material respects, all the undertakings relating thereto. No submissions made to any Governmental Authority in connection with obtaining any Grant contained any misstatement or omission that would have affected the granting of such Grant. As of the date hereof, the Company has not been informed in writing by a Governmental Authority that they have any intent to revoke or materially modify any of the Grants. To the Company’s knowledge, the consummation of the transactions contemplated by this Agreement in and of itself will not have any adverse effect on the continued validity and effectiveness of any such Grants. Each Subsidiary has, in accordance with applicable Law, duly registered with the relevant Governmental Authority and obtained and maintained the validity of all national and local tax registration certificates. To the Company’s knowledge, the Company has not taken or omitted to take any action that can reasonably be expected to form the basis of any Governmental Authorities rejecting the renewal or extension of the Grants with respect to the High-Technology Enterprise status as the current three-year term of such status is due to expire.
Grants and Benefits. There are no material pending and outstanding grants, incentives and subsidies, and applications therefore, in each case with a value of more than $20,000.00, from any Governmental Authority, or from any foreign Governmental Authority, granted to the Company or the Subsidiaries.
Grants and Benefits. Schedule 2.27 of the Company Disclosure Schedule provides a complete list as of the date hereof of all pending and outstanding grants, incentives and subsidies, and applications therefor (collectively, “Grants”) from the government of the State of Israel or any agency thereof, or from any foreign governmental or administrative agency, granted to the Company or any of its Subsidiaries, including, without limitation, (i) Approved Enterprise Status from the Investment Centre and (ii) grants from the Office of the Chief Scientist (the “OCS”). The Company provided to Buyer, prior to the date hereof, true and correct copies of all documents evidencing Grants submitted by the Company or any of its Subsidiaries and all letters of approval, and supplements thereto, granted to the Company or any of its Subsidiaries. Schedule 2.27 of the Company Disclosure Schedule includes the aggregate amounts of each Grant, and the aggregate outstanding obligations thereunder of the Company or any of its Subsidiaries with respect to royalties, or the outstanding amounts to be paid by the OCS to the Company or any Subsidiary. Except as set forth on Schedule 2.27 of the Company Disclosure Schedule, the Company or such Subsidiary, as appropriate, is in compliance, in all material respects, with the terms and conditions of their respective Grants and has duly fulfilled, in all material respects, all the undertakings relating thereto. The Company is not aware of any event or other set of circumstances which might lead to the revocation or material modification of any of the Grants.
Grants and Benefits. (a) Schedule 4.25 provides a complete list of all pending and outstanding grants, incentives and subsidies, and applications therefor (collectively, “Grants”) from the government of the State of Israel or any agency thereof, or from any foreign governmental or administrative agency, (i) granted to the Company or (ii) based solely on the representations of Imarad included in the Imarad Purchase Agreement, granted to any other entity from which the Company has purchased the Purchased Assets (a “Predecessor Entity”) and the obligations in respect of which the Company expressly assumed or assumed by operation of law that the Company or Parent is aware of, including, Approved Enterprise Status from the Investment Center and Benefited Plants from the Israeli Tax Authority and the Office of the Chief Scientist. Neither Parent nor the Company has received any funding from the Office of the Chief Scientist that in any way restricts the Company’s ability to transfer, license, use or exploit any of the Purchased Assets or Parent’s ability to perform under Section 3.4(b).
Grants and Benefits. Schedule 3.12 provides a complete list of all pending and outstanding grants, incentives and subsidies, and applications therefore (collectively, “Grants”) from the government of the State of Israel or any agency thereof, or from any foreign governmental or administrative agency, granted to the Company or the Subsidiary, including, without limitation, (i) Approved Enterprise Status from the Investment Centre, (ii) grants from the Office of the Chief Scientist (the “OCS”) and (iii) grants from the BIRD Foundation. The Purchaser has received true and accurate copies of all documents evidencing Grants submitted by the Company or the Subsidiary and of all letters of approval, and supplements thereto, granted to the Company or the Subsidiary. Schedule 3.12 includes the aggregate amounts of each Grant, and the aggregate outstanding obligations thereunder of the Company or the Subsidiary with respect to royalties, or the outstanding amounts to be paid by the OCS to the Company or the Subsidiary. The Company or the Subsidiary, as appropriate, is in compliance, in all material respects, with the terms and conditions of their respective Grants and has duly fulfilled, in all material respects, all the undertakings relating thereto. The Seller is not aware of any event or other set of circumstances which might lead to the revocation or material modification of any of the Grants. To the best knowledge of the Company, there are no outstanding liabilities on the part of the Company of the Subsidiary to make any royalty or other payment with respect to the Grants.
Grants and Benefits
